Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Visx/Alcon Laboratories

This article was originally published in The Gray Sheet

Executive Summary

Firms sign letter of intent under which Visx "for a negotiated fee" will make use of Alcon's "resources and expertise" to guide a voluntary review of Visx clinical investigative sites. FDA recently sent Form 483 inspectional observation reports to two of Visx's 26 investigative sites ("The Gray Sheet" Sept. 12, p. 13). However, Visx maintains that its decision to conduct the independent reviews "was neither requested nor required by the FDA." The agreement also calls for Alcon to provide further "regulatory services" to Visx "on an ongoing basis." In addition, Visx announces that Alcon Chairman, CEO and President Edgar Schollmaier will rejoin Visx' board of directors; Schollmaier served on the Visx board from 1987 to 1993



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts